Adamas Pharmaceuticals focuses on a portfolio of therapies to reduce the burden of neurological diseases on patients, caregivers, and society. Co.'s portfolio includes: GOCOVRI® (amantadine) extended release capsules for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and as adjunctive treatment for patients with Parkinson's disease taking levodopa/carbidopa experiencing reemergence or sudden return of stiffness, rigidity and tremors; and OSMOLEX ER® (amantadine) extended release tablets for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The ADMS average annual return since 2014 is shown above.
The Average Annual Return on the ADMS average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ADMS average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ADMS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|